Hematology-Oncology Associates of the Quad-Cities, PC
Lung Cancer Trials
C30801: A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing
Advanced Non-Small Cell Lung Cancer
NO8CA: The Use of Glutathione (GSH) for Prevention of TAXOL/CBDCA Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study
CTSU E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
CALGB 30605 A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer.
CALGB 30704: Phase II Study of Pemetrexed or Sunitinib or Pemetrexed plus Sunitinib in the 2nd line Treatment of Advanced NSCLC.
E5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Genentech OAM4971g: Phase III, Double-blind, Placebo-Controlled Study Evaluating the efficacy and safety of MetMab in combination with Tarceva in patients with met diagnostic positive non small cell lung cancer who have received standard
Chemotherapy for advanced or metastatic disease
Advanced Non-Small Cell Lung Cancer
NO8CA: The Use of Glutathione (GSH) for Prevention of TAXOL/CBDCA Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study
CTSU E1505: A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
CALGB 30605 A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer.
CALGB 30704: Phase II Study of Pemetrexed or Sunitinib or Pemetrexed plus Sunitinib in the 2nd line Treatment of Advanced NSCLC.
E5508: Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Genentech OAM4971g: Phase III, Double-blind, Placebo-Controlled Study Evaluating the efficacy and safety of MetMab in combination with Tarceva in patients with met diagnostic positive non small cell lung cancer who have received standard
Chemotherapy for advanced or metastatic disease
